Synlogic stock.

Chg %. Market Cap. Molecular Templates Inc. 4.65%. $33.48M. SYBX | Complete Synlogic Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …

Synlogic stock. Things To Know About Synlogic stock.

Synlogic has also developed two drug candidates through a research collaboration with Ginkgo Bioworks: SYNB1353, designed to consume methionine for the potential treatment of HCU, and SYNB2081, designed to lower uric acid for the potential treatment of gout.Synlogic Inc stock performance at a glance. Check Synlogic Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and …6.12%. $26.33M. SYBX | Complete Synlogic Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.The latest Synlogic stock prices, stock quotes, news, and SYBX history to help you invest and trade smarter.

September 27, 2023 at 12:31 pm EDT. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that it will implement a 1-for-15 Reverse Stock Split …What is the target price for Synlogic (SYBX) stock? A. The latest price target for Synlogic ( NASDAQ: SYBX) was reported by Chardan Capital on Friday, August 11, 2023. The analyst firm set a price ...

Mar 8, 2023 · CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B ... 2.46. +0.16. +6.96%. Get Synlogic Inc (SYBX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Synlogic Stock Probability Of Bankruptcy ... Stocks USA . ... Synlogic Probability Of Bankruptcy is used to show its chance of financial distress over the next two ...Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic ...Grading Synlogic Inc Stock. Before you choose to buy, sell or hold Synlogic Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement.Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ...Since its IPO on the Shenzhen stock exchange, its share price has gone up every day by the exact same amount. Baofeng Technologies is China’s best performing stock this year. Since its IPO on the Shenzhen stock exchange, its share price has...

Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

٠١‏/١٢‏/٢٠٢٢ ... SQZ BiotechSynlogiclayoffsChutes and Ladders. Share. water The industry's rocky conditions have created a vacuumlike layoff sinkhole that ...

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?About Synlogic Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat ...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Mar 8, 2023 · CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B ... Summary of all time highs, changes and price drops for Synlogic; Historical stock prices; Current Share Price: US$2.56: 52 Week High: US$16.50: 52 Week Low: …Synthetic biology is an entirely new strategy in drug development, affording us the opportunity to design selective and potent living medicines to treat disease. With a team of experienced scientists and executives at the helm, Synlogic is forging new ground to advance this approach and design novel therapeutics to treat unmet medical needs. ٠١‏/١٢‏/٢٠٢٢ ... SQZ BiotechSynlogiclayoffsChutes and Ladders. Share. water The industry's rocky conditions have created a vacuumlike layoff sinkhole that ...

Synlogic another drug, SYNB1353, had received RPDD in December 2022 to treat homocystinuria (HCU), according to the company. SYBX +12.95% to $1.12 premarket Jan. 19 Recommended For YouCAMBRIDGE, Mass. and BOSTON, Nov. 9, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the nomination of SYNB1353, an …Ginkgo has purchased 6,340,771 shares of Synlogic common stock as well as pre-funded warrants to purchase up to 2,548,117 shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The transactions were executed and closed on June 11, 2019.Dec 15, 2022 · Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash ... Jun 12, 2019 · Ginkgo has purchased 6,340,771 shares of Synlogic common stock as well as pre-funded warrants to purchase up to 2,548,117 shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The transactions were executed and closed on June 11, 2019.

CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update. “Last year was a tremendous year for …The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts.

Synlogic Announces Reverse Stock Split. September 27, 2023. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), ...Share. Share. Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering. Stock Information for Synlogic Inc. Loading. Please wait while we ...Synthetic biology is an entirely new strategy in drug development, affording us the opportunity to design selective and potent living medicines to treat disease. With a team of experienced scientists and executives at the helm, Synlogic is forging new ground to advance this approach and design novel therapeutics to treat unmet medical needs.Third Quarter 2022 Financial Results. As of September 30, 2022, Synlogic had cash, cash equivalents and short-term investments of $91.7 million. Revenue for the three months ended September 30, 2022 was $0.7 million compared to $0.9 million for the corresponding period in 2021. Revenue in both periods was associated with the ongoing research ...CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU). “We are …Nov 9, 2023 · Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October ... Synlogic Announces Reverse Stock Split. September 27, 2023. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), ...Institutional investors have sold a total of 13,539,674 shares in the last 24 months. This volume of shares sold represents approximately $97.33M in transactions. Iterum Therapeutics Institutional Ownership. This page (NASDAQ:SYBX) was last updated on 11/16/2023 by MarketBeat.com Staff.CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU).

Stock Information. Stock Quote & Chart; Analyst Coverage; Corporate Governance. Governance Highlights; Management Team; Board of Directors; Committee …

We are driven by the promise of synthetic biology and by the new possibilities for better health that we believe we can bring to patients. Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease. Find the latest Synlogic, Inc. (SYBX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...On average, Wall Street analysts predict. that Synlogic's share price could reach $82.50 by Aug 11, 2024. The average Synlogic stock price prediction forecasts a potential upside of 4,025% from the current SYBX share price of $2.00. CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...Historical daily share price chart and data for Synlogic since 2015 adjusted for splits and dividends. The latest closing stock price for Synlogic as of November 27, 2023 is 1.97.. …Synlogic was spun out of MIT and uses technology developed by Drs. Tim Lu and Jim Collins. Synlogic was founded in 2014 and became a public company via a reverse merger in 2017. The first ...Sep 27, 2023 · Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. Cash runway expected into H2 2024. CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and ...

The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuriaCAMBRIDGE, Mass., March 20 ...Synlogic, Inc. (SYBX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 1.8600 -0.0300 (-1.59%) At close: 04:00PM EDT 1.8400 -0.02 (-1.08%) After …Following the reverse split, shares are trading at about $3.95 this morning. SYBX stock is down 5.6% as of Thursday morning, with some 2,000 shares changing hands. For the record, the company’s ...Instagram:https://instagram. hot stocks under a dollarsunny loancommercial real estate debttrade options in ira The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. stock trading trackeriphone 14 pro sold out Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic ... 1943 penny worth money Since its IPO on the Shenzhen stock exchange, its share price has gone up every day by the exact same amount. Baofeng Technologies is China’s best performing stock this year. Since its IPO on the Shenzhen stock exchange, its share price has...Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ...Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic ...